Microcap Ledger Genprex, Inc. $GNPX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Austin, TX
- Fiscal year end
- December 31
- Shares outstanding
- 819,709 [10-Q 2026-08-14]
What the company doesAI summary of filing
Genprex is a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its lead oncology product, REQORSA, is a non-viral gene therapy delivering the TUSC2 tumor suppressor gene to cancer cells and is being tested in combination with approved cancer drugs for non-small cell lung cancer and small cell lung cancer. The company's diabetes program, GPX-002, uses an adeno-associated virus vector to deliver genes into the pancreas and is in preclinical development for Type 1 and Type 2 diabetes. Genprex is pre-revenue and generates no product sales; it is funded through equity offerings and operates clinical trials and research collaborations. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$8.91M | −$8.28M | $15.15M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$16.23M | −$15.31M | $7.83M | [DEF 14A 2026-04-29] |
| FY ended Dec 2024 | $0.00 | −$21.39M | −$17.92M | $1.60M | [10-K 2025-04-01] |
- Quarterly cash burn
- −$4.14M
- Cash runway Estimate
- ~11 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 8,508,068 | [10-Q 2024-11-13] |
| 2025-03-28 | 24,152,848 | [10-K 2025-04-01] |
| 2025-05-09 | 27,821,136 | [10-Q 2025-05-12] |
| 2025-08-01 | 33,466,784 | [10-Q 2025-08-14] |
| 2025-11-13 | 2,270,346 | [10-Q 2025-11-14] |
| 2026-03-27 | 9,044,856 | [10-K 2026-03-30] |
| 2026-05-11 | 10,586,402 | [10-Q 2026-05-13] |
| 2026-08-10 | 819,709 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2026-06-05; no effectiveness notice found in EDGAR [S-3 2026-06-05]
Listing status
Current status: 9 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-05. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-05 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-05] |
| 2026-07-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-30] |
| 2026-06-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-12] |
| 2025-11-26 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-11-26] |
| 2025-10-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-10-17] |
| 2025-08-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-08-20] |
| 2025-06-09 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-09] |
| 2025-02-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-12] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-04-14 | Longnecker Brent M | sell | 8 | $1.23 | [4 2026-04-15] |
| 2026-04-14 | Longnecker Brent M | sell | 10 | $1.23 | [4 2026-04-15] |
| 2026-02-27 | Berger Mark Stanley | other | 7,168 | $2.00 | [4 2026-02-27] |
| 2026-02-27 | Confer Ryan M. | other | 9,330 | $2.00 | [4 2026-02-27] |
| 2025-12-22 | Moreno Toscano Jose Antonio | grant | 9,000 | — | [4 2025-12-23] |
| 2025-12-22 | Berger Mark Stanley | grant | 28,500 | — | [4 2025-12-23] |
| 2025-12-22 | Confer Ryan M. | grant | 45,000 | — | [4 2025-12-23] |
| 2025-12-22 | Longnecker Brent M | grant | 9,000 | — | [4 2025-12-23] |
| 2025-12-22 | Wilson William R Jr. | grant | 9,000 | — | [4 2025-12-23] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-18 | 8-K | Other events |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Listing notice or transfer |
| 2026-08-03 | 8-K | Other events |
| 2026-07-30 | 8-K | Listing notice or transfer; Other events |
| 2026-07-14 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-06-22 | 8-K | Other events |
| 2026-06-18 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-12 | 8-K | Listing notice or transfer; Other events |
| 2026-06-05 | S-3 | Registration statement |
| 2026-05-26 | 8-K | Other events |
| 2026-05-14 | 8-K | Other events |
Alerts for $GNPX
Email me when Genprex, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.